Skip to main content
Year archive

Pluri Inc. — 2023 filings

All 89 regulatory filings released by Pluri Inc. (PLUR) in 2023, sourced directly from the official regulator.

89 Filings
2023 Period
2023 filings (89)
Filing Released Lang
Form 10Q For the quarterly period ended September 30, 2023
Interim / Quarterly Report Q1 2023
2023-11-14 English
Form 10Q For the quarterly period ended September 30, 2023
Report Publication Announcement
2023-11-14 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2024
2023-11-13 English
Received a letter from Nasdaq approving an extension of an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement
Delisting Announcement
2023-10-20 English
Received a letter from Nasdaq approving an extension of an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement
Report Publication Announcement
2023-10-20 English
CURRENT REPORT
Regulatory Filings
2023-10-19 English
Regulatory Filings 2023
Regulatory Filings
2023-09-22 English
Regulatory Filings 2023
Regulatory Filings
2023-09-19 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2023-09-15 English
FORM S-3/A (Amendment No. 1)
Capital/Financing Update
2023-09-13 English
FORM S-3/A (Amendment No. 1)
Report Publication Announcement
2023-09-13 English
FORM 10-K For the fiscal year ended June 30, 2023
Annual Report FY 2023
2023-09-13 English
FORM 10-K For the fiscal year ended June 30, 2023
Report Publication Announcement FY 2023
2023-09-13 English
AMENDMENT NO. 1 TO FORM S-3
Registration Form
2023-09-12 English
ANNUAL REPORT
Annual Report FY 2023
2023-09-12 English
Pluri’s PLX-R18 Increases Blood Cell Counts & Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantatio
Regulatory Filings
2023-08-16 English
Pluri’s PLX-R18 Increases Blood Cell Counts & Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantatio
Report Publication Announcement
2023-08-16 English
Regulatory Filings 2023
Regulatory Filings
2023-07-25 English
FORM S-3- PROSPECTUS
Capital/Financing Update
2023-07-21 English
FORM S-3- PROSPECTUS
Regulatory Filings
2023-07-21 English
REGISTRATION STATEMENT
Registration Form
2023-07-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Abony Lorne Kenneth
Director's Dealing
2023-07-13 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Abony Lorne Kenneth
Director's Dealing
2023-07-13 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Abony Lorne Kenneth
Major Shareholding Notification
2023-07-13 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Abony Lorne Kenneth
Director's Dealing
2023-07-13 English
8K-Appointment of Entrepreneur Lorne Abony to Board of Directors
Board/Management Information
2023-07-13 English
8K-Appointment of Entrepreneur Lorne Abony to Board of Directors
Report Publication Announcement
2023-07-13 English
Appointment of Entrepreneur Lorne Abony to Board of Directors
Board/Management Information
2023-07-13 English
Appointment of Entrepreneur Lorne Abony to Board of Directors
Regulatory Filings
2023-07-13 English
Director's Dealing 2023
Director's Dealing
2023-07-13 English
Director's Dealing 2023
Director's Dealing
2023-07-13 English
CURRENT REPORT
Regulatory Filings
2023-07-13 English
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Sy
Regulatory Filings
2023-07-11 English
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Sy
Report Publication Announcement
2023-07-11 English
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Sy
Regulatory Filings
2023-07-11 English
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Sy
Report Publication Announcement
2023-07-11 English
CURRENT REPORT
Regulatory Filings
2023-07-11 English
Regulatory Filings 2023
Regulatory Filings
2023-06-09 English
Regulatory Filings 2023
Regulatory Filings
2023-06-06 English
Regulatory Filings 2023
Regulatory Filings
2023-06-05 English
FORM S-3-REGISTRATION STATEMENT
Capital/Financing Update
2023-06-02 English
FORM S-3-REGISTRATION STATEMENT
Report Publication Announcement
2023-06-02 English
REGISTRATION STATEMENT
Registration Form
2023-06-01 English
Form 10-Q -March 31, 202 3Financial Results
Interim / Quarterly Report 9M 2023
2023-05-10 English
Form 10-Q -March 31, 202 3Financial Results
Report Publication Announcement
2023-05-10 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2023
2023-05-09 English
Results of stockholder voting at the 2023 Annual Meeting held on April 27, 2023
AGM Information
2023-04-28 English
Results of stockholder voting at the 2023 Annual Meeting held on April 27, 2023
Report Publication Announcement
2023-04-28 English
CURRENT REPORT
Regulatory Filings
2023-04-27 English
Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
Regulatory Filings
2023-04-27 English
Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products
Regulatory Filings
2023-04-27 English
received a Notice from Nasdaq regurding the $1.00 per share minimum required for continued listing on the Nasdaq
Delisting Announcement
2023-04-26 English
received a Notice from Nasdaq regurding the $1.00 per share minimum required for continued listing on the Nasdaq
Report Publication Announcement
2023-04-26 English
8-K
Regulatory Filings
2023-04-25 English
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender
Environmental & Social Information
2023-03-13 English
Israel’s Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender
Report Publication Announcement
2023-03-13 English
2022 ANNUAL REPORT
Annual Report FY 2022
2023-02-27 English
2022 ANNUAL REPORT
Report Publication Announcement
2023-02-27 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On April 27, 2023
Proxy Solicitation & Information Statement
2023-02-27 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On April 27, 2023
Proxy Solicitation & Information Statement
2023-02-27 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On April 27, 2023
AGM Information
2023-02-27 English
FORM ARS
Annual Report
2023-02-27 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2023-02-27 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On April 27, 2023, POXY STATEMENT
Proxy Solicitation & Information Statement
2023-02-16 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held On April 27, 2023, POXY STATEMENT
Remuneration Information
2023-02-16 English
PRELIMINARY PROXY STATEMENT
Regulatory Filings
2023-02-16 English
SCHEDULE 13G
Major Shareholding Notification
2023-02-16 English
8K- Amendment No. 1 to correct the date of the 2023 Annual Meeting, which will be held on April 27, 2023
Regulatory Filings
2023-02-14 English
8K- Amendment No. 1 to correct the date of the 2023 Annual Meeting, which will be held on April 27, 2023
Report Publication Announcement
2023-02-14 English
AMENDMENT NO. 1 TO FORM 8-K
Regulatory Filings
2023-02-14 English
S-8-Registration statement, common shares that may issued pursuant to company 2016
Share Issue/Capital Change
2023-02-14 English
S-8-Registration statement, common shares that may issued pursuant to company 2016
Report Publication Announcement
2023-02-14 English
S-8-Registration statement, common shares that may issued pursuant to company 2016  
Share Issue/Capital Change
2023-02-14 English
S-8-Registration statement, common shares that may issued pursuant to company 2016  
Report Publication Announcement
2023-02-14 English
FORM 10-Q-report for the quarterly period ended December 31, 2022
Interim / Quarterly Report Q2 2022
2023-02-14 English
FORM 10-Q-report for the quarterly period ended December 31, 2022
Report Publication Announcement
2023-02-14 English
REGISTRATION STATEMENT
Registration Form
2023-02-13 English
REGISTRATION STATEMENT
Registration Form
2023-02-13 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2023
2023-02-13 English
Annual Meeting of Shareholders to be held on April 20, 2023
AGM Information
2023-02-06 English
Annual Meeting of Shareholders to be held on April 20, 2023
Report Publication Announcement
2023-02-06 English
AMENDMENT NO. 1 TO SCHEDULE 13G
Major Shareholding Notification
2023-02-06 English
CURRENT REPORT
Regulatory Filings
2023-02-06 English
Received a letter from Nasdaq notifying that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2)
Regulatory Filings
2023-01-25 English
Received a letter from Nasdaq notifying that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2)
Regulatory Filings
2023-01-25 English
CURRENT REPORT
Regulatory Filings
2023-01-24 English
SCHEDULE 13D- Yaky Yanay
Major Shareholding Notification
2023-01-05 English
SCHEDULE 13D- Yaky Yanay
Major Shareholding Notification
2023-01-05 English
SCHEDULE 13D
Major Shareholding Notification
2023-01-04 English